Deal on comprehensive reform of EU pharmaceutical legislation | News
Regulatory data and market protection to support innovation Parliament and Council negotiators agreed to a regulatory data protection period (during which other companies cannot access product data) of eight years, with one additional year of market protection (during which generic or biosimilar products cannot be sold), following a marketing authorisation. Pharmaceutical companies would be eligible […]
